Form D · Pharmaceuticals

Edgemont Pharmaceuticals, LLC

Mendham, NJ · CIK 0001488709

Offering snapshot reported Dec 9, 2010 · SEC filing

Reported sold: $4.85M
Investors reported: 32
Minimum accepted: $10K
First sale: Mar 22, 2010

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$1,310,000 → $4,845,795
Reported investors11 → 32
Minimum accepted$100,000 → $10,000

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Dec 9, 2010	Amendment	$4,845,795	$3,535,795vs Apr 7, 2010	32	SEC filing
Apr 7, 2010	Amendment	$1,310,000	$0vs Apr 6, 2010	11	SEC filing
Apr 6, 2010	Initial	$1,310,000	No comparison	11	SEC filing

Offering details

Securities: Equity, Security to be acquired
Exemptions: 06
Duration over one year: No
Business combination: No

Sales commissions: $290K
Finders' fees: $0
Form D file number: 021-140230

The offering is completed.

Sales compensation recipients

Scroll to see all columns →

Recipient	CRD	Associated broker-dealer
Riverbank Capital Securities, Inc.	135310

Source: Form D, filed Dec 9, 2010. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Christine Blumhardt	Executive
Barbara Duncan	Director
Timothy Mc Inerney	Director
Douglas A. Saltel	Director, Executive
Warren Stern	Executive
Mike Vachon	Executive
Robert Zerbe	Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:

88 East Main Street Suite 506
Mendham, NJ, 07945